MEDGADGET EDITORSMEDICINE, NEUROLOGY, NEUROSURGERY, REHAB

The MemorEM system from NeuroEM Therapeutics, a company based in Phoenix, Arizona, delivers transcranial electromagnetic treatment, or TEMT, to the brains of patients in two one-hour sessions each day for two months. This involves propagating electromagnetic waves toward β-amyloid aggregates that seem to be responsible for the symptoms of Alzheimer’s. In animal studies, it was shown that TEMT does indeed prevent β-amyloid aggregates from forming and even disrupts existing conglomerations.

In a study on eight patients who went through the regimen described above, all but one showed either a pause or reversal in cognitive decline, a remarkable achievement for a non-drug therapy. There doesn’t seem to be substantial side effects, so larger studies will hopefully commence soon.

Study: A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer’s Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging

Via: NeuroEM Therapeutics (PDF)